G007-LK Tankyrase 1/2 Inhibitor: Mechanism, Evidence, and Research Utility

Executive Summary: G007-LK is a highly selective small-molecule inhibitor targeting tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2), with IC50 values of 46 nM and 25 nM, respectively, in auto-poly-(ADP ribosyl)ation assays (APExBIO). It suppresses Wnt/β-catenin signaling in cellular models, achieving an IC50 of 0.05 μM for ST-Luc reporter inhibition in Wnt3a-induced HEK 293 cells (Jia et al., 2017). G007-LK induces degradasome formation and β-catenin degradation in APC-mutant colorectal cancer cells, and reduces tumor growth in COLO-320DM xenograft mouse models. In hepatocellular carcinoma, G007-LK also downregulates YAP via Hippo pathway modulation. The compound is insoluble in water and ethanol but highly soluble in DMSO (≥26.5 mg/mL), allowing for robust integration into research workflows.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribosyl)ating polymerases (PARPs) involved in the regulation of Wnt/β-catenin signaling, telomere maintenance, and cell cycle progression (Jia et al., 2017). Aberrant Wnt/β-catenin signaling is implicated in colorectal cancer, particularly in cases harboring APC mutations (Amadacycline.com). Tankyrase-mediated degradation of AXIN destabilizes the β-catenin destruction complex, promoting β-catenin accumulation and oncogenic signaling. Inhibiting tankyrase stabilizes AXIN1/2, enhancing β-catenin degradation and suppressing Wnt pathway activity. Additionally, tankyrase activity modulates Hippo pathway effectors, such as YAP, impacting tumor growth in hepatocellular carcinoma. These mechanisms justify the use of G007-LK in dissecting cancer cell signaling and evaluating therapeutic strategies targeting tankyrase-dependent pathways.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK is a synthetic, small-molecule inhibitor designed for high affinity and selectivity toward TNKS1 and TNKS2 (APExBIO). It binds the catalytic PARP domain of tankyrases, preventing auto-poly(ADP-ribosyl)ation. This inhibits the tankyrase-mediated ubiquitination and degradation of AXIN proteins. Resulting AXIN stabilization promotes assembly of the β-catenin destruction complex, leading to β-catenin phosphorylation, recruitment of β-TrCP, and proteasomal degradation. In APC mutant colorectal cancer cells, this results in reduced cytosolic and nuclear β-catenin levels, transcriptional inhibition of Wnt target genes, and induction of dynamic degradasomes marked by phosphorylated β-catenin, β-TrCP, and ubiquitin (Adrenorphin.net). G007-LK also blocks tankyrase-dependent degradation of angiomotin-like proteins (AMOTL1/2), which are negative regulators of YAP, resulting in Hippo pathway activation and further limiting tumor cell proliferation (Jia et al., 2017).

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC50 values of 46 nM and 25 nM, respectively, under biochemical assay conditions (APExBIO, product page).
• In Wnt3a-induced HEK293 cells, G007-LK suppresses Wnt/β-catenin signaling reporter ST-Luc activity with an IC50 of 0.05 μM (Jia et al., 2017).
• In APC-mutant colorectal cancer cell lines (e.g., SW480), G007-LK induces degradasomes containing phosphorylated β-catenin, β-TrCP, and ubiquitin, promoting β-catenin degradation (Amadacycline.com).
• In COLO-320DM xenograft mouse models, G007-LK reduces both tankyrase and β-catenin protein levels, stabilizes AXIN1/2, and suppresses tumor growth (APExBIO).
• G007-LK decreases YAP protein levels, inhibits YAP/TEAD luciferase reporter activity, and upregulates AMOTL1/2 in hepatocellular carcinoma cell lines (Jia et al., 2017).
• G007-LK demonstrates synergy with MEK and AKT inhibitors in suppressing cancer cell proliferation (Jia et al., 2017).

This article extends prior guides (e.g., adrenorphin.net) by emphasizing Hippo pathway and YAP modulation, and integrates recent in vivo results for translational cancer research.

Applications, Limits & Misconceptions

G007-LK is primarily used for research on Wnt/β-catenin signaling, tankyrase biology, and APC mutation colorectal cancer models (mouse-ifn-a.com). It is also relevant for hepatocellular carcinoma studies due to its impact on the Hippo/YAP axis. The specificity and potency of G007-LK enable mechanistic studies dissecting the roles of tankyrase in cancer cell signaling and β-catenin turnover. However, certain cell types or tumor models lacking Wnt pathway dependence may show minimal response. Efficacy in vivo is limited by solubility constraints (DMSO only; insoluble in water/ethanol), and long-term solution storage is discouraged due to compound instability. G007-LK is not approved for clinical use and should only be used in research settings.

Common Pitfalls or Misconceptions

• G007-LK is not effective in Wnt-independent tumors; its action is specific to models with active tankyrase-mediated Wnt signaling.
• Solubility is limited to DMSO; attempts to dissolve in water or ethanol will fail, potentially compromising experimental reproducibility.
• Not suitable for in vivo use in humans; G007-LK is for preclinical research only, not for therapeutic or diagnostic applications.
• Storing G007-LK solutions long-term leads to degradation; solid storage at -20°C is required for stability (APExBIO).
• Interpretation of results must consider potential off-target effects at high concentrations; always include appropriate controls.

Workflow Integration & Parameters

G007-LK is provided as a solid by APExBIO (SKU: B5830), recommended for storage at -20°C. For experimental use, dissolve in DMSO to ≥26.5 mg/mL. For optimal solubility, warming to 37°C or brief ultrasonic bath treatment is suggested. Avoid repeated freeze-thaw cycles and prolonged storage of stock solutions. In cell-based assays, initial testing in the 0.01–1 μM range is standard, with specific concentrations optimized per system (Amadacycline.com). In vivo studies use DMSO-based formulations in murine models. G007-LK can be combined with MEK or AKT inhibitors to probe pathway crosstalk or potential therapeutic synergy. For detailed workflows and troubleshooting, see this protocol-focused article, which this guide expands by integrating YAP and Hippo pathway evidence.

Conclusion & Outlook

G007-LK is a validated, nanomolar-potency tankyrase 1/2 inhibitor enabling precise interrogation of Wnt/β-catenin and Hippo signaling in cancer models. Its robust selectivity and well-characterized mechanism underpin its value for APC mutation colorectal cancer and hepatocellular carcinoma research. Future studies may further clarify its translational relevance, especially in combinatorial regimens targeting Wnt and Hippo pathways. For more information, see the G007-LK tankyrase 1/2 inhibitor product page at APExBIO.